Abstract Objective To study the effect of astragaloside IV (AS-IV) on NOD-like receptor protein 3 (NLRP3) inflammasome in neonatal rats with hypoxic-ischemic brain damage (HIBD). Methods A total of 24 Sprague-Dawley rats, aged 7 days, were randomly divided into a sham-operation group, an HIBD group, and an AS-IV treatment group, with 8 rats in each group. After 24 hours of modeling, brain tissue was collected for hematoxylin-eosin staining, yo-PRO-1 staining, and EthD-2 immunofluorescent staining in order to observe the cerebral protection effect of AS-IV in vivo. HT22 cells were used to prepare a model of oxygen-glycogen deprivation (OGD), and a concentration gradient (50-400 μmol/L) was established for AS-IV. CCK-8 assay was used to measure the viability of HT22 cells. RT-PCR and Western blot were used to observe the effect of different concentrations of AS-IV on the mRNA and protein expression of NLRP3, gasdermin D (GSDMD), caspase-1, and interleukin-1β (IL-1β). Results Yo-Pro-1 and EthD-2 staining showed that compared with the sham-operation group, the HIBD group had an increase in pyroptotic cells with a small number of necrotic cells, and the AS-IV group had reductions in both pyroptotic and necrotic cells. Compared with the sham-operation group, the HIBD group had significantly higher protein expression levels of NLRP3, IL-1β, caspase-1, and GSDMD (P < 0.05). Compared with the HIBD group, the AS-IV group had significant reductions in the protein expression levels of NLRP3, caspase-1, and GSDMD (P < 0.05). HT22 cell experiment showed that compared with the OGD group, the AS-IV group had inhibited mRNA and protein expression of NLRP3, GSDMD, caspase-1, and IL-1β, with the best therapeutic effect at the concentration of 200 μmol/L (P < 0.05). Conclusions AS-IV may alleviate HIBD in neonatal rats by inhibiting the expression of NLRP3, GSDMD, caspase-1, and IL-1β.
LI Na,MU Ya-Ping,LIU Chun-Ying et al. Effect of astragaloside IV on the expression of NOD-like receptor protein 3 inflammasome in neonatal rats with hypoxic-ischemic brain damage[J]. CJCP, 2021, 23(4): 402-409.
LI Na,MU Ya-Ping,LIU Chun-Ying et al. Effect of astragaloside IV on the expression of NOD-like receptor protein 3 inflammasome in neonatal rats with hypoxic-ischemic brain damage[J]. CJCP, 2021, 23(4): 402-409.
Nonomura M, Harada S, Asada Y, et al. Combination therapy with erythropoietin, magnesium sulfate and hypothermia for hypoxic-ischemic encephalopathy:an open-label pilot study to assess the safety and feasibility[J]. BMC Pediatr, 2019, 19(1):13.
[2]
Kim YE, Sung SI, Chang YS, et al. Thrombin preconditioning enhances therapeutic efficacy of human Wharton's jelly-derived mesenchymal stem cells in severe neonatal hypoxic ischemic encephalopathy[J]. Int J Mol Sci, 2019, 20(10):2477.
[3]
Laptook AR, Shankaran S, Tyson JE, et al. Effect of therapeutic hypothermia initiated after 6 hours of age on death or disability among newborns with hypoxic-ischemic encephalopathy:a randomized clinical trial[J]. JAMA, 2017, 318(16):1550-1560.
[4]
Shankaran S, Laptook AR, Pappas A, et al. Effect of depth and duration of cooling on death or disability at age 18 months among neonates with hypoxic-ischemic encephalopathy:a randomized clinical trial[J]. JAMA, 2017, 318(1):57-67.
[5]
Jacobs SE, Morley CJ, Inder TE, et al. Whole-body hypothermia for term and near-term newborns with hypoxic-ischemic encephalopathy:a randomized controlled trial[J]. Arch Pediatr Adolesc Med, 2011, 165(8):692-700.
[6]
Yang Y, Wang HN, Kouadir M, et al. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors[J]. Cell Death Dis, 2019, 10(2):128.
[7]
Aridas JD, Yawno T, Sutherland AE, et al. Detecting brain injury in neonatal hypoxic ischemic encephalopathy:closing the gap between experimental and clinical research[J]. Exp Neurol, 2014, 261:281-290.
[8]
Paramel Varghese G, Folkersen L, Strawbridge RJ, et al. NLRP3 inflammasome expression and activation in human atherosclerosis[J]. J Am Heart Assoc, 2016, 5(5):e003031.
[9]
Serdar M, Kempe K, Rizazad M, et al. Early pro-inflammatory microglia activation after inflammation-sensitized hypoxic-ischemic brain injury in neonatal rats[J]. Front Cell Neurosci, 2019, 13:237.
[10]
Ystgaard MB, Sejersted Y, Løberg EM, et al. Early upregulation of NLRP3 in the brain of neonatal mice exposed to hypoxia-ischemia:no early neuroprotective effects of NLRP3 deficiency[J]. Neonatology, 2015, 108(3):211-219.
Song MT, Ruan J, Zhang RY, et al. Astragaloside IV ameliorates neuroinflammation-induced depressive-like behaviors in mice via the PPARγ/NF-κB/NLRP3 inflammasome axis[J]. Acta Pharmacol Sin, 2018, 39(10):1559-1570.
[13]
Li M, Li HY, Fang F, et al. Astragaloside IV attenuates cognitive impairments induced by transient cerebral ischemia and reperfusion in mice via anti-inflammatory mechanisms[J]. Neurosci Lett, 2017, 639:114-119.
[14]
Dixon BJ, Reis C, Ho WM, et al. Neuroprotective strategies after neonatal hypoxic ischemic encephalopathy[J]. Int J Mol Sci, 2015, 16(9):22368-22401.
[15]
Zhang Y, Zhang Y, Jin XF, et al. The role of Astragaloside IV against cerebral ischemia/reperfusion injury:suppression of apoptosis via promotion of P62-LC3-autophagy[J]. Molecules, 2019, 24(9):1838.
[16]
Buyukakilli B, Atici A, Balli E, et al. Effects of a tumor necrosis factor-alpha inhibitor (etanercept) on the sciatic nerve in a hypoxic ischemia-induced neonatal rat model[J]. Adv Clin Exp Med, 2014, 23(5):705-713.
[17]
Wang HH, Zhou XY, Li H, et al. Transient receptor potential melastatin 2 negatively regulates LPS-ATP-Induced caspase-1-dependent pyroptosis of bone marrow-derived macrophage by modulating ROS production[J]. Biomed Res Int, 2017, 2017:2975648.
[18]
Rat P, Olivier E, Tanter C, et al. A fast and reproducible cell- and 96-well plate-based method for the evaluation of P2X7 receptor activation using YO-PRO-1 fluorescent dye[J]. J Biol Methods, 2017, 4(1):e64.
Silveira RC, Procianoy RS. Hypothermia therapy for newborns with hypoxic ischemic encephalopathy[J]. J Pediatr (Rio J), 2015, 91(6 Suppl 1):S78-S83.
[21]
Wang HL, Zhou QH, Xu MB, et al. Astragaloside IV for experimental focal cerebral ischemia:preclinical evidence and possible mechanisms[J]. Oxid Med Cell Longev, 2017, 2017:8424326.
Huang J, Lu WT, Doycheva DM, et al. IRE1α inhibition attenuates neuronal pyroptosis via miR-125/NLRP1 pathway in a neonatal hypoxic-ischemic encephalopathy rat model[J]. J Neuroinflammation, 2020, 17(1):152.
[30]
Liao H, Wang HX, Rong XM, et al. Mesenchymal stem cells attenuate radiation-induced brain injury by inhibiting microglia pyroptosis[J]. Biomed Res Int, 2017, 2017:1948985.
[31]
McKenzie BA, Mamik MK, Saito LB, et al. Caspase-1 inhibition prevents glial inflammasome activation and pyroptosis in models of multiple sclerosis[J]. Proc Natl Acad Sci U S A, 2018, 115(26):E6065-E6074.
[32]
Kuang SY, Zheng J, Yang H, et al. Structure insight of GSDMD reveals the basis of GSDMD autoinhibition in cell pyroptosis[J]. Proc Natl Acad Sci U S A, 2017, 114(40):10642-10647.
[33]
Pichl T, Keller T, Hünseler C, et al. Effects of ketamine on neurogenesis, extracellular matrix homeostasis and proliferation in hypoxia-exposed HT22 murine hippocampal neurons[J]. Biomed Rep, 2020, 13(4):23.
